RecruitingNCT06777628
Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
Immunophenotype of Peripheral Blood Mononuclear Cells to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
100 participants
Start Date
Sep 15, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for: * predicting response to immune-therapeutic regimens in HCC in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- age ≥ 18 years
- diagnosis of HCC
- execution of laboratory tests and subsequent treatments and follow-up at our center.
- obtained written informed consent to the study participation
Exclusion Criteria2
- immune-related concomitant diseases
- HIV infection
Interventions
DRUGImmunochemotherapy combined with antiangiogenic
Immunochemotherapy combined with antiangiogenic
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06777628
Related Trials
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
NCT057052193 locations
RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study
NCT0734524720 locations
An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer
NCT073156331 location
NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
NCT072952621 location
T-Cell Therapy (ECT204) in Adults With Advanced HCC
NCT048640547 locations